Zanidatamab + chemotherapy (Ct) ± tislelizumab for first-line (1l) HER2-positive (Her2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (Mgea): Primary analysis from HERIZON-GEA-0
Elimova, E., Rha, S. Y., Shitara, K., Liu, T., Tabernero, J., Lee, K.-W., Schenker, M., Tebbutt, N. C., Ajani, J. … Read More
